Q2 2024 Dyadic International Inc Earnings Call Transcript
Key Points
- Dyadic International Inc (DYAI) is strategically positioned to achieve multiple revenue streams and significant milestones over the next 24 months through product commercialization, technology licensing, and collaborations.
- The company's C1 technology is gaining widespread recognition for its speed and productivity, with endorsements from academia, government agencies, and top pharmaceutical collaborators.
- Dyadic's Dapibus protein expression platform is generating revenue in the alternative protein and bioindustrial sectors, showcasing its commercial potential.
- The partnership with Proliant Health and Biologicals for recombinant serum albumin is expected to unlock opportunities in a $6 billion market, with anticipated recurring revenue starting in 2025.
- Dyadic is actively expanding its presence in the alternative protein sector, with developments in recombinant products like DNASE-1 and transferrin, targeting high-growth markets.
- Revenue for the quarter ended June 30, 2024, decreased significantly to approximately $386,000 from $837,000 a year ago, due to the winding down of large research collaborations.
- Research and development expenses decreased, reflecting the winding down of activities related to the company's Phase 1 clinical trial and internal projects, indicating a potential slowdown in R&D activities.
- General and administrative expenses increased, driven by higher share-based compensation, legal, and business development expenses, impacting overall profitability.
- The company reported a net loss of approximately $2,045,000 for the quarter, consistent with the previous year's loss, highlighting ongoing financial challenges.
- There was a delay in achieving success in the non-animal dairy enzymes project, impacting the timeline for receiving a success fee and potential revenue.
Good evening and welcome to the Dyadic International's Q2 2024 conference call. (Operator Instructions) As a reminder, this conference is being recorded today, August 13, 2024.
I would like to now turn the conference over to Ms. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.
Thank you. Good evening and welcome, everyone, to Dyadic International's Q2 2024 conference call. I hope you have had the opportunity to review Dyadic's press releases announcing financial results for the quarter ended June 30, 2024. You may access our release and Form 10-Q under the investors section of the company's website at dyadic.com.
On today's call, our President and CEO, Mark Emalfarb; and our Chief Operating Officer, Joe Hazelton, will give a review of our second quarter 2024 business and corporate highlights, including a brief summary of our recent research and business development efforts. I will follow with a review of our financial results in more detail. And our Chairman,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
